Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • No longer available  
  • Page 1 ·  Next »

NCT ID: NCT04802083 No longer available - Covid19 Clinical Trials

COVID-19 Soliris Expanded Access Protocol

Start date: n/a
Phase:
Study type: Expanded Access

This protocol provides participants with COVID-19 access to Soliris.

NCT ID: NCT04798066 No longer available - Clinical trials for Post COVID-19 Syndrome

Intermediate Size Expanded Access Protocol Evaluating HB-adMSC's for the Treatment of Post-COVID-19 Syndrome

LongHaulers
Start date: n/a
Phase:
Study type: Expanded Access

This is an Intermediate- Size Patient Population Expanded Access Protocol to evaluate the safety and efficacy of HB-adMSCs for the treatment of patients with Post-COVID-19 Syndrome. The investigational product will be an add-on treatment to the standard of care.

NCT ID: NCT04603651 No longer available - COVID-19 Clinical Trials

Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

NCT ID: NCT04476706 No longer available - Clinical trials for Cytokine Release Syndrome in COVID-19-induced Pneumonia

Canakinumab MAP in COVID-19 Pneumonia With CRS

Start date: n/a
Phase:
Study type: Expanded Access

This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia

NCT ID: NCT04374370 No longer available - COVID Clinical Trials

SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)

Start date: n/a
Phase:
Study type: Expanded Access

Convalescent plasma has been administered to treat different infectious diseases previously with some success. There is currently no approved and proven treatment options available for the novel coronavirus disease (COVID-19 virus). Some early data has shown a potential benefit in treating hospitalized patients who have tested positive for COVID-19 with convalescent plasma infusions of fresh plasma donated by fully recovered COVID-19 patients. The antibodies present in the recovered patients' plasma may be of benefit in helping critically ill and infected patients recover from the COVID-19 virus.

NCT ID: NCT04372368 No longer available - COVID-19 Clinical Trials

Convalescent Plasma for the Treatment of Patients With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access program will provide access to COVID-19 convalescent plasma 150 or more individuals with moderate to severe or life-threatening manifestations of COVID-19, or documented to be at high risk of developing such manifestations at participating hospitals in Colorado.COVID-19 convalescent plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19. Convalescent plasma collected from individuals who have recovered from COVID-19 contains antibodies to SARS-CoV-2. Preliminary evidence and data collected during other respiratory virus outbreaks (including the 2003 SARS-CoV-1 epidemic, the 2009-2010 H1N1 influenza virus pandemic, and the 2012 MERS-CoV epidemic) suggest that the antibodies in convalescent plasma may be effective in fighting the infection.

NCT ID: NCT04366830 No longer available - Clinical trials for Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

Start date: n/a
Phase:
Study type: Expanded Access

The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019 (COVID-19).

NCT ID: NCT04358588 No longer available - COVID-19 Clinical Trials

Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

The search for novel therapies to address the ongoing coronavirus (COVID-19) pandemic is ongoing. No proven therapies have been identified to prevent progression of the virus. Preliminary data suggest that inhaled nitric oxide (iNO) could have benefit in preventing viral progression and reducing reliance on supplemental oxygen and ventilator support. Expanded access allows for iNO to be delivered via the portable INOpulse delivery system for the treatment of COVID-19.

NCT ID: NCT04358211 No longer available - COVID-19 Clinical Trials

Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

I. Study Design: This is a single-arm feasibility study to assess the safety and efficacy of anti-SARS-CoV-2 convalescent plasma (CP) in 1. intubated, mechanically ventilated patients with confirmed COVID-19 pneumonia by chest X-ray or chest CT. 2. hospitalized patients with acute respiratory symptoms between 3 and 7 days after the onset of symptoms, with COVID-19. II. Study Population: 1. Population 1: Mechanically ventilated intubated COVID-19 patients aged 18 years or older. 2. Population 2: Hospitalized COVID-19 patients aged ≥18 years of age with respiratory symptoms within 3 to 7 days from the beginning of illness. III. Study Agent: SARS-CoV-2 convalescent plasma (1-2 units; ~200-400 mL at neutralization antibody titer >1:160.

NCT ID: NCT04355494 No longer available - COVID-19 Clinical Trials

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This protocol provides access to eculizumab treatment for participants with severe COVID-19.